Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1ion Nov 20, 2023 2:22pm
174 Views
Post# 35744864

mdjbrown, I checked the couch for any spare loose change and

mdjbrown, I checked the couch for any spare loose change andhere's why.   Pidduck showed a great deal of confidence in this recent conference call to disclose that they and their pharma partner are waiting for FDA approval for a generic version of Epidiolex.  He then drops a clue big enough to figure it out quite easily w.r.t. to one of Brazil's largest generic makers having recently completed an acquisition....late September closing a deal by Eurofarm puts them as the strongest candidate.  Eurofarm covering all of South America as well as activity in the U.S. and Europe as a generic drug maker.  It doesn't take long to connect the dots that for South America, Brazil, ANVISA pending approval that it too is probably for a generic version of Epidiolex as well.   

In summary, based on those disclosures made during the last CC I personally take it as a strong level of confidence from Pidduck AND therefore we are in the zone of MAJOR NEWS PENDING!!!


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse